- Home
- EVRG vs BBIO Comparison
EVRG vs BBIO Comparison
Compare EVRG & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVRG | BBIO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 14.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | EVRG | BBIO |
|---|---|---|
| Price | $73.46 | $78.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 21 |
| Target Price | ★ $78.75 | $78.71 |
| AVG Volume (30 Days) | 1.9M | ★ 2.1M |
| Earning Date | 02-26-2026 | 02-19-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $5,878,800,000.00 | $353,780,000.00 |
| Revenue This Year | $4.78 | $127.64 |
| Revenue Next Year | $4.13 | $78.38 |
| P/E Ratio | $20.06 | ★ N/A |
| Revenue Growth | 1.75 | ★ 62.46 |
| 52 Week Low | $59.67 | $28.10 |
| 52 Week High | $79.32 | $78.59 |
Technical Indicators
Market Signals| Indicator | EVRG | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.10 | 61.90 |
| Support Level | $72.56 | $70.95 |
| Resistance Level | $73.95 | $78.36 |
| Average True Range (ATR) | 0.95 | 2.95 |
| MACD | 0.18 | -0.18 |
| Stochastic Oscillator | 77.86 | 86.98 |
Price Performance
Historical ComparisonAbout EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission. The utility has a combined rate base of more than $20 billion, about half in Kansas and the rest split between Missouri and interstate transmission. Evergy is one of the largest wind energy suppliers in the US.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.